Slingshot members are tracking this event:

Celgene Presents Long Term Safety Data on Oral Otezla

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Clinical Data Celgene announced long term safety data pooled from 182-week (3.5-year) safety data from the ESTEEM 1 and 2 trials and 3-year safety data from the PALACE 1-3 trials.  The pooled data showed no increases in the severity or frequency of adverse events and no new safety signals.  The rates of major cardiac events, malignancies, depression and suicidality at 182 weeks were comparable to those at 52 weeks.  No serious opportunistic infections, reactivation of tuberculosis, or clinically meaningful effects on laboratory measurements were reported through 182 weeks
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 07, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Otezla, Long Term Safety Data, Plaque Psoriasis, Apremilast, Phosphodiesterase 4, Esteem Trial